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Abstract
Various synthetic derivatives of natural flavonoids are known to have neuroactive properties.  The
present study aimed to investigate the effects of vitexin (5, 7, 4-trihydroxyflavone-8-glucoside), a
flavonoid found in such plants as tartary buckwheat sprouts, wheat leaves phenolome, Mimosa pudica
Linn and Passiflora spp, on scopolamine-induced memory impairment in rats.  To achieve this goal, we
assessed the effects of vitexin on memory retrieval in the presence or absence of scopolamine using a
step-through passive avoidance trial.  In the first part of the study, vitexin (25, 50, and 100 µM) was
administered intracerebroventricularly (i.c.v.) before acquisition trials.  In the second part, vitexin, at
the same doses, was administered before scopolamine (10 µg, i.c.v.) and before the acquisition trials.
During retention tests, vitexin (100 µM) in the absence of scopolamine significantly increased the step-
through latencies compared to scopolamine.  In addition, vitexin (100 µM) significantly reversed the
shorter step-through latencies induced by scopolamine (P < 0.05).  These results indicate that vitexin has
a potential role in enhancing memory retrieval.  A possible mechanism is modulation of cholinergic
receptors; however, other mechanisms may be involved in its effects in acute exposure.
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Introduction
Flavonoids are a group of structurally related
phenyl benzopyrones.  They are subdivided into the
following main classes: flavones, flavanones, fla-
vonols, isoflavones, flavans and flavan-3-ols.  Because
they are found in all plants, they are constituents of
the human diet (13).  Flavonoid derivatives have been
considered useful in treatment for neurodegenerative
disorders such as Alzheimer disease (AD) (45).
In recent years, several mechanisms have been
examined for signalling pathways that underlie
improved cognitive function; flavonoids activate the
extracellular signal-regulated protein kinase cAMP-
response element-binding protein (ERK-CREB)
pathway and the phosphoinositide 3-kinase-mTOR
(PI3-kinase-mTOR) cascade, leading to changes in
synaptic plasticity.  They are also capable of influ-
encing neurogenesis through the activation of PI3-
kinase-AkteNOS (44).  Moreover, flavonoids have
been reported to block oxidative-induced neuronal
damage by preventing the activation of caspase-3,
thus, providing evidence in support of their potent
anti-apoptotic action (37).
In a brain-imaging study of humans, the con-
sumption of flavanol-rich cocoa was shown to enhance
cortical blood flow (8).  This result is important for
increasing cerebrovascular function, especially in the
hippocampus, a brain region that is important for
memory and that may facilitate adult neurogenesis
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(10).  New hippocampal cells are clustered near blood
vessels that proliferate in response to vascular growth
factors and may influence memory (29).
Several lines of evidence suggest that flavonoids
have beneficial effects on memory and learning (39).
The effects of flavonoid-rich foods and pure fla-
vonoids on neurocognitive ability have been shown
in rodents (14, 16, 18, 47).  Rodent models have been
used as models of human declarative memory to
predict the potential effects of flavonoids on human
cognitive performance (34).  Previous reports have
also established a role for flavonoids in preventing
human dementia (5).  It has shown that flavonoids
have acetylcholinesterase inhibitory activities (20,
42).
Scopolamine is used as a standard drug for in-
ducing cognitive deficits in healthy humans and
animals (21).  Scopolamine is a muscarinic receptor
antagonist with amnestic properties and is a widely
used model for characterizing potential cognition-
enhancing drugs (8).  Blockade of central muscarinic
receptors may induce a pattern of cognitive impair-
ment in AD patients (4).
Vitexin (5, 7, 4-trihydroxyflavone-8-glucoside)
is a c-glycosilated flavone often found in plants such
as tartary buckwheat sprouts, wheat leaves phenolome,
Mimosa pudica Linn and Passiflora spp (25, 31, 46,
48).  It has been reported that vitexin has several phar-
macological properties, including antinociceptive,
antispasmodic, antimyeloperoxidase and α-glucosi-
dase inhibitory activities (11, 12, 23, 32, 33, 38).  In
addition, vitexin has been shown to have free radical
scavenging activity in ultraviolet B (UVB)-irradiated
cultured human dermal fibroblasts (19).  Recently,
we have shown that vitexin has anticonvulsant effects
in rats treated with pentylenetetrazole (PTZ) (1).
In the present study, two sets of experiments
were conducted.  We first investigate the dose-
response of vitexin alone, followed by the effects
of vitexin with scopolamine interactions.
Materials and Methods
Animals
Male Wistar rats (200-250 g) were obtained
from the Razi Institute (Karaj, Iran) and housed in
groups of four per cage under standard laboratory
conditions.  They were kept at constant room tem-
perature (21 ± 2°C) under a normal 12 h light/12 h
dark (12L:12D) regime with free access to food and
water.  All the animal experiments were performed
in accordance with the European Communities Coun-
cil Directive of November 24, 1986 (86/609/EEC)
to minimize the number of animals and their suf-
fering.
Drugs
Vitexin was purchased from Fluka (Buches,
Swetzerland).  The other drugs used in this study
were ketamine (Rotexmedica, GmbH, Germany) and
xylazine (Loughrea Co, Galway, Ireland).  Scopola-
mine was purchased in an injectable form from Daru
Pakhsh (Tehran, Iran).  Vitexin was dissolved in
saline.  Vitexin, scopolamine and saline were admin-
istered intracerebroventricularly (i.c.v.) in a volume
of 5 µl.
Surgery and Experimental Procedures
All the rats were anesthetized with ketamine
(60 mg/kg, i.p.) and xylazine (6 mg/kg, i.p.) and
placed in a stereotaxic apparatus (Stoelting, Wood
Dale, IL, USA).  The skull surface was exposed, and
the head was oriented such that the bregma and lamb-
da skull sutures were at the same vertical levels.
Stereotaxic coordinates for the left lateral ventricle
were: anterior-posterior (AP), -0.92 mm from bregma;
medial-lateral (ML), 1.6 mm from the midline; and
dorsal-ventral (DV), 3.5 mm from the skull surface
(30).  For chronic i.c.v. cannulation, a stainless steel
guide cannula (21-gauge) was implanted to terminate
1 mm above the left lateral ventricle (2.4 mm ventral
from the skull surface).  This cannula was attached
to the skull with a stainless steel screw and dental
acrylic cement.  Housed individually, the rats were
allowed to recover from surgery for at least a week.
On the day of the experiment, the rats were transferred
to the experimental room 1 h prior to the experi-
ment.  For intracerebroventricular drug administra-
tion, the rats were gently hand restrained and drug
infusions were made using an injection needle (24-
gauge) inserted into the guide cannula connected
through a polyethylene tube to a 5 µl Hamilton sy-
ringe (28).
Experimental Procedure
The rats were divided into eight groups of 10
animals each.  The first group was administered saline
(5 µl, i.c.v) 30 min before acquisition trials.  The
second group received scopolamine (10 µg, i.c.v.)
30 min before the acquisition trials.  The next three
groups received vitexin (25, 50 or 100 µM, i.c.v.) 30
min before the acquisition trials.  In the remaining
three groups, vitexin (25, 50 or 100 µM, i.c.v.) was
administered 15 min before scopolamine (10 µg,
i.c.v.) and 45 min before the acquisition trials.
Passive Avoidance Apparatus
The passive avoidance apparatus comprised of
186 Abbasi, Nassiri-Asl, Sheikhi and Shafiee
a learning box consisting of a light (white) and a
dark (black) compartment, 20 × 20 × 30 cm each.  A
guillotine door opening (6 × 6 cm) was made on the
floor in the center of the partition between the two
compartments.  Stainless steel grids (5 mm in diameter)
were placed at 1 cm intervals (distance between the
centers of grids) on the floor of the dark compartment
to produce a foot shock (Borj Sanat, Tehran, Iran).
All the rats were allowed to habituate to the
experimental room for at 30 min prior to the experi-
ments.  This standard was applied across experiments
both in the vitexin dose response and the vitexin with
scopolamine treatment.  Then, each rat was gently
placed in the light compartment of the apparatus.
After 5 sec, the guillotine door was opened and the
rat was allowed to enter the dark compartment.  The
latency with which each rat crossed into the dark
compartment was recorded.  The rats that waited
more than 100 sec to cross into the dark compartment
were eliminated from the experiments.  Once the rat
crossed with all four paws into the next compartment,
the guillotine door was closed and the rat was returned
to its home cage.  The acquisition trial was performed
30 min after the habituation trial.  The rat was placed
in the light compartment, and the guillotine door was
opened 5 sec later.  As soon as the rat crossed into
the dark compartment, the door was closed and a
foot shock (0.5 mA intensity, 3 sec) was immediately
delivered to the grid floor of the dark room by an
insulated stimulator (26).  One day after training,
retention tests were performed to evaluate memory
performance.  Each rat was placed in the light com-
partment for 20 sec, the door was opened, and the
step-through latency for entering into the dark
compartment was measured.  The test session ended
when the rat entered the dark compartment or re-
mained in the light compartment for 300 sec.  No elec-
tric shock was applied during these sessions (27).
Histology
At the end of the experiments, the rats were
injected with 2 µl of crystal violet and deeply anes-
thetized.  Their brains were removed and fixed in 10%
formaldehyde solution.  For histological examination
of the cannula and needle placement in the lateral
ventricle region, 100 µm-thick sections were taken
and the cannula track was examined in each rat.  Only
those rats whose cannulae were exactly placed in the
left ventricle were used for further analysis (28).
Thus, only behavioral results for animals with correct
cannula placement were considered.
Data Analysis
The data were analyzed three times as follows:
[1] control versus scopolamine treatment analyzed
by Student’s t-test, [2] vitexin dose response com-
paring with the control vs. 25, 50 or 100 µM vitexin
analyzed by one-way ANOVA, [3] vitexin with sco-
polamine treatment analyzed by one-way ANOVA.
A probability P < 0.05 was considered statistically
significant.
Results
Histological evaluation of the brains of control
and drug treated rats confirmed that in all rats in
each group, the cannula were in correct position
(Fig. 1).
The step-through latency times were not sig-
nificantly different between the experimental and
control groups during the acquisition test (Fig. 2A).
During the retention test, the step-through latency
of the scopolamine-treated group was significantly
lower than that of the control group (P < 0.05) (t-test)
(Fig. 2B).
The step-through latencies of the groups treated
with vitexin alone (25, 50 or 100 µM) were not sig-
nificant at the studied doses compared to the control
(one-way ANOVA, Tukey-Kramer test).
However, vitexin alone at a dosage of 100 µM
significantly increased the step-through latency com-
pared to scopolamine treatment (one-way ANOVA,
Tukey-Kramer test) (Fig. 2B).
The step-through latencies of the groups treated
with vitexin (25, 50 or 100 µM) with scopolamine
were not significant at the studied doses compared
to the control (one-way ANOVA, Tukey-Kramer
test).
Furthermore, in the analysis of the groups treated
with vitexin (25, 50 or 100 µM) with scopolamine by
Fig. 1. Schematic representation of cannula sites aimed unilat-
erally at the intracerebroventricular (icv) region using
the stereotaxic atlas of Paxinos and Watson (30).  Cor-
rect placement of cannula tips of ten animals were shown
by filled circles.
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one-way ANOVA, vitexin (100 µM) significantly
reversed the shorter step-through latencies of
scopolamine (P < 0.05) (one-way ANOVA, Tukey-
Kramer test) (Fig. 2B).
Discussion
Data of the present study show that the step-
through latency of the scopolamine-treated group
was significantly lower than that of the control group
in the retention test.  Vitexin alone at 100 µM signifi-
cantly increased the step-through latency compared
to scopolamine.
Vitexin administration prior to scopolamine
in the acquisition trials is followed by attenuated
impairment retention of the avoidance test in rats.
Vitexin at a dose of 100 µM significantly reversed
scopolamine-induced memory impairment.
Despite some limitations that it fails to replicate
the pathological aspects and the progressive degenera-
tive nature of Alzheimer’s disease (43), scopolamine-
induced memory impairment, particularly when
coupled with a version of the inhibitory avoidance
task, provides a relatively rapid phenotypic screening
tool for drug discovery in the field of cognition en-
hancement (7).  Similar results have been obtained
for other related compounds such as rutin, quercetin,
resveratrol and curcuminoids, all of which showed
potential protective effects against scopolamine-
induced memory impairment (3, 9, 35).
One of the receptors proposed to act as a
flavonoid-binding site in neurons is the GABAA
receptor (2, 15).  Muscarinic receptor subtypes are
localized in pyramidal and nonpyramidal cells in the
hippocampus (22).  It has been shown that muscarinic
receptors can enhance GABAergic synaptic trans-
mission through a presynaptic and postsynaptic
mechanism (49).  The rapid release of GABA in re-
sponse to acetylcholine is mediated by a different
subtype of muscarinic receptors (24).  Activation of
cholinergic receptors seems to cause direct excita-
tion of GABAergic interneurons (17).  Moreover,
GABAergic inhibition is known to control the flow
of information in a cortical circuit that is important
for performance of certain forms of memory (6).
These findings suggest that vitexin possibly acts via
modulation of the GABAergic system to attenuate
scopolamine-induced memory impairment.  For this
reason, the effects of vitexin on memory were more
significant in the presence of scopolamine.
As an active component of Urtica circularis,
vitexin has shown potent antinociceptive effects in a
chemical model of nociception in mice.  The possible
role of cholinergic activation has been discussed for
antinociceptive effects of the extract (13).  Further-
more, as the role of acetylcholinesterase inhibitory
activity of flavonoids, vitexin could have cholinergic
properties (20, 42).  As shown by our results, it is pos-
Fig. 2. Effects of vitexin and scopolamine on the step-through latencies in acquisition trials (A) and retention trials (B) in rats.  In
the first group, saline (5 µl, i.c.v.) was given 30 min before the acquisition trial.  Memory impairment was induced by scopola-
mine treatment (10 µg, i.c.v.), and acquisition trial was carried out 30 min after its treatment.  Rats were injected vitexin (25,
50 or 100 µM, i.c.v.) 30 min before the acquisition trials.  For the study on the effects of vitexin on the scopolamine-induced
memory deficits model, rats were administered vitexin (25, 50 or 100 µM, i.c.v.) 15 min before scopolamine (10 µg, i.c.v.)
and 45 min before the acquisition trials (A).  At 24 h after the acquisition trials, retention trials were done (B).  Values are
expressed as means ± SEM (n = 10).  *P < 0.05, compared to control (t-test); #P < 0.05, compared to scopolamine-treated
group, Tukey-Kramer test.
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sible that vitexin improves cognition by modulating
cholinergic neurotransmission.
The efficacy of flavonoids on memory perfor-
mance is dependent on the period of their adminis-
tration.  It seems that the mechanisms of acute and
chronic flavonoid administration are different (40).
Flavonoids have been shown to influence peripheral
and central blood flow.  Based on both in vitro and
in vivo studies, these vascular effects are potentially
significant because increased cerebrovascular func-
tion is known to facilitate adult neurogenesis in the
hippocampus (10, 36).  After consumption of flavonol-
rich foods, cerebral blood flow rapidly increases in a
certain region of the human brain (8).  It has been
suggested that increased cerebral blood flow exerts
impacts on acute cognitive performance (41).  More-
over, it has been shown that flavonoids may have the
potential to reduce brain amyloid-beta (Aß) levels
by improving cerebral blood flow (45).  However, it
should be considered that increased cerebral blood
flow occurs both on acute and chronic exposure.
In the present study, it is possible that vitexin
directly interacts with cholinergic or/and GABAergic
neurons and attenuates scopolamine-induced memory
impairment in the passive avoidance task.  Alterna-
tively, vitexin may act indirectly and activate some
signaling pathway by increasing cerebral blood flow.
However, further investigation is required to clarify
this issue.
Our behavioral study shows that vitexin admin-
istration can attenuate scopolamine-induced memory
impairment in rats.  Vitexin administration prior to
training trials in passive avoidance tests resulted in
improved memory retrieval, which was observed in
the retention tests.  It is possible that vitexin acts by
several mechanisms that play potential roles in
memory retrieval in rats.  Further studies are necessary
to evaluate the effects of vitexin on memory retention
and to determine its molecular mechanisms.
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